SR604
Brief description of study
Primary- testing of the safety and tolerability at increasing doses of SR604 given every 4 weeks subcutaneously in subjects with hemophilia A or B with or without inhibitors. Secondary- testing the pharmacokinetics (PK) and clinical activity of SR604 Exploratory- testing the immunogenicity, pharmacodynamics by way of SR604 activity, inflammatory responses, and any functional modulation that occurs Incidence of AES/SAEs, abnormal/changed lab values, bodily changes assessed by physicals and vital signs. PK values and clinical activity assessed by bleeding incidences.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
